Vimian Group AB (publ) (VIMIAN.ST)

SEK 42.2

(2.93%)

Market Cap (In SEK)

21.81 Billion

Revenue (In SEK)

331.73 Million

Net Income (In SEK)

9.84 Million

Avg. Volume

589.15 Thousand

Currency
SEK
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
25.14-47.2
PE
-
EPS
-
Beta Value
1.597
ISIN
SE0015961982
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
Mr. Patrik Eriksson
Employee Count
-
Website
https://vimian.com
Ipo Date
2021-06-18
Details
Vimian Group AB (publ) engages in the animal health business worldwide. It operates through Specialty Pharma, MedTech, Diagnostics, and Veterinary Services segments. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic solutions that are used by laboratories for veterinary specific applications with a focus on livestock and companion animal health markets under the Indical Bioscience brand name. It also provides procurement and tech-driven operations, such as online marketing, and education and HR, as well as a community for veterinary clinics through a membership-based platform under the VetFamily brand name; and orthopedic implants for veterinarians and universities under the Movora brand name. The company was incorporated in 2020 and is headquartered in Stockholm, Sweden.

More Stocks